IDEAYA Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
IDYA$32.03+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances as of January 1, 2021 | 29,537,216 | $3 | $325,250 | $7 | $(126,986) | $198,274 |
| Issuance of common stock upon follow-on public offering, net of issuance costs | 5,333,333 | 1 | 85,989 | — | — | 85,990 |
| Issuance of common stock related to at-the-market offering program, net of issuance costs | 3,407,872 | — | 57,263 | — | — | 57,263 |
| Issuance of common stock upon exercise of stock options | 211,900 | — | 1,510 | — | — | 1,510 |
| Employee stock purchase plan (ESPP) purchase | 50,037 | — | 697 | — | — | 697 |
| Repurchase of unvested restricted stock | (7,313) | — | — | — | — | — |
| Vesting of early exercised common stock options and restricted stock | — | — | 24 | — | — | 24 |
| Stock-based compensation | — | — | 8,237 | — | — | 8,237 |
| Other comprehensive loss | — | — | — | (719) | — | (719) |
| Net loss | — | — | — | — | (49,762) | (49,762) |
| Balances as of December 31, 2021 | 38,533,045 | 4 | 478,970 | (712) | (176,748) | 301,514 |
| Issuance of common stock upon follow-on public offering, net of issuance costs | 8,761,905 | 1 | 86,080 | — | — | 86,081 |
| Issuance of common stock related to at-the-market offering program, net of issuance costs | 601,844 | — | 8,842 | — | — | 8,842 |
| Issuance of common stock upon exercise of stock options | 214,643 | — | 1,448 | — | — | 1,448 |
| Employee stock purchase plan (ESPP) purchase | 81,742 | — | 755 | — | — | 755 |
| Stock-based compensation | — | — | 11,629 | — | — | 11,629 |
| Other comprehensive loss | — | — | — | (2,159) | — | (2,159) |
| Net loss | — | — | — | — | (58,655) | (58,655) |
| Balances as of December 31, 2022 | 48,193,179 | 5 | 587,724 | (2,871) | (235,403) | 349,455 |
| Issuance of common stock upon follow-on public offering, net of issuance costs | 14,655,993 | 2 | 281,120 | — | — | 281,122 |
| Issuance of pre-funded warrants for the purchase of common stock | — | — | 42,182 | — | — | 42,182 |
| Issuance of common stock related to at-the-market offering program, net of issuance costs | 1,188,705 | — | 28,598 | — | — | 28,598 |
| Issuance of common stock upon exercise of stock options | 931,012 | — | 9,559 | — | — | 9,559 |
| Employee stock purchase plan (ESPP) purchase | 70,480 | — | 1,213 | — | — | 1,213 |
| Stock-based compensation | — | — | 18,489 | — | — | 18,489 |
| Other comprehensive gain | — | — | — | 3,433 | — | 3,433 |
| Net loss | — | — | — | — | (112,961) | (112,961) |
| Balances as of December 31, 2023 | 65,039,369 | $7 | $968,885 | $562 | $(348,364) | $621,090 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.